Attorney General Jeffrey S. Chiesa

GSK agrees to pay $90 million to settle diabetes drug allegations


GlaxoSmithKline will pay a $90 million settlement to 38 states that claimed it unlawfully promoted its diabetes treatment Avandia (rosiglitazone). The attorneys general of several states confirmed the action on Thursday.

Don't miss any McKnight's news